Study shows no higher cancer risk with Vytorin
A new study published in the Journal of Clinical Lipidology shows no increased cancer risk with US drug majors Merck & Co and Schering-Plough's Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin), compared to cancer rates for other powerful lipid-lowering statin therapies.
Researchers studied rates of reports of cancer as an adverse event filed with the US Food and Drug and Administration for patients taking Zetia or Vytorin compared to those on mono-therapy with Merck's Zocor (simvastatin), global drug giant Pfizer's Lipitor (atorvastatin) or Anglo-Swedish drug major AstraZeneca's Crestor (rosuvastatin), during a four-year period.
The analysis found cancer reported in 2.9 per million prescriptions for Zetia, 1.3 per million prescriptions for Vytorin therapy and an average of 4.1 per million prescriptions for other lipid-lowering treatment. These rates demonstrate no increase in cancer for Zetia and Vytorin regimen versus the other treatments studied.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze